Myeloma 2015 | Optimizing proteasome inhibitors for the treatment of multiple myeloma

Robert Orlowski

At the Myeloma 2015 meeting, Prof Robert Orlowski (MD Anderson Cancer Center, Houston, TX) discusses multiple novel proteasome inhibitors in clinical development that have shown promising activity for the treatment of multiple myeloma. Rationally based combination therapies involving proteasome inhibitors may offer a new option to overcome drug resistance.

Share this video  
Related videos
Myeloma XI trial: increased progression-free survival
Charlotte Pawlyn
Pivotal STORM study: selinexor for penta-refractory multiple myeloma
Joshua Richter
Current challenges for multiple myeloma therapy: 2, 3, 4-drug combinations
Joshua Richter
Multiple myeloma musings: highlights from 2018 data
Joshua Richter
An exciting era for CAR T-cell therapy
Mohamad Mohty
Multiple Myeloma
Myeloma 2015
11th April 2015
More from Robert Orlowski
How can novel targets be incorporated into MM treatment?
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals